Teva Undertaking Strategic Review As It Searches For New CEO
Executive Summary
Execs were pushed for details during earnings call but offer minimal clarity. Teva is sticking by the guidance issued before its loss in Copaxone patent case, and is upping investment in promoting the brand while the decision is appealed.
You may also be interested in...
Teva To Divest Women's Health, Some Oncology As CEO Search Proceeds
The company is pursuing the sale of global women's health and its oncology and pain businesses in Europe, Interim CEO Yitzhak Peterburg said during the firm's first quarter earnings call.
Teva To Divest Women's Health, Some Oncology As CEO Search Proceeds
The company is pursuing the sale of global women's health and its oncology and pain businesses in Europe, Interim CEO Yitzhak Peterburg said during the firm's first quarter earnings call.
Teva Catches A Break On Copaxone 40mg, But For How Long?
An FDA warning letter cites deficiencies at the Pfizer-owned manufacturing facility poised to produce a Momenta/Sandoz generic competitor. It’s unclear how long Pfizer might take to resolve the violations, which include particulates in finished products.